在结直肠癌中,HADHB调解了5-甲的敏感性
1Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Discover oncology
|August 28, 2025
概括
过度表达的HADHB蛋白与结直肠癌 (CRC) 中的5甲抗性有关. 向HADHB-DUOX2-ROS通路可能会提高CRC患者的5FU治疗疗效.
科学领域:
- 癌症学
- 分子生物学
- 生物化学
背景情况:
- 5FU是结直肠癌的基石化疗法.
- 药物耐药性,特别是对5FU的耐药性,显著限制了CRC治疗的有效性.
- 在CRC中的5FU耐药性中,Hydroxyacyl- CoA脱酶β子单元 (HADHB) 的作用尚不清楚.
研究的目的:
- 研究HADHB在结直肠癌中调节5FU敏感性的作用.
- 确定HADHB作为克服CRC5FU耐药性的治疗标的潜力.
主要方法:
- 对CRC组织进行免疫组合化学分析,以将HADHB表达与5FU疗效相关联.
- 细胞活力测试 (CCK-8) 评估HADHB对CRC细胞系中的5FUIC50的影响.
- 共同免疫沉 (Co-IP),光染色和流动细胞测量以识别与HADHB相互作用的蛋白质并测量活性氧物种 (ROS) 水平.
- 代谢学和转录学研究DUOX2相关的代谢途径.
主要成果:
- 与敏感组织相比,耐5FU的CRC组织中的HADHB表达显著更高.
- 在CRC细胞中降低HADHB增强了5FU敏感性,诱导了细胞亡,并导致细胞循环停止.
- DUOX2被确定为一种与HADHB相互作用的新型蛋白质,它们的相互作用调节了ROS的产生.
- HADHB-DUOX2-ROS途径与调节5FU敏感性有关.
结论:
- 在结直肠癌中,HADHB的过度表达与5FU耐药性有关.
- HADHB-DUOX2-ROS轴代表了一个潜在的驱动5FU电阻的机制.
- 针对HADHB可能是克服CRC5FU耐药性的可行策略.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
01:15Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264